

Room temperature HFIP/Ag-Promoted Palladium-Catalyzed C–H Functionalization of Benzothiazole with Iodoarenes.

Santosh Kori^{a,b}, Yuvraj Bhujbal^a, Kamlesh Vadagaonkar^a, Anant R. Kapdi^{a,*}, Saidurga Prasad Kommyreddy^c, Santosh J. Gharpure^c

^aDepartment of Chemistry, Institute of Chemical Technology, Nathalal Parekh Road, Matunga, Mumbai – 400019, India

^bInstitute of Chemical Technology-Indian Oil Odisha Campus, IIT Kharagpur Extension Centre, Mouza Samantpuri, Bhubaneswar – 751013, Odisha, India

^cDepartment of Chemistry, Indian Institute of Technology Bombay, Powai, Mumbai – 400076, India

Corresponding author: ar.kapdi@ictmumbai.edu.in

Table of Contents

| | |
|--|----|
| • General remarks | 2 |
| • Representative procedures | 3 |
| • Characterization data for substituted benzothiazoles | 4 |
| • Schemes with footnotes | 13 |
| • ¹ H and ¹³ C NMRs spectra's for substituted benzothiazoles | 16 |
| • ¹ H NMR experiments data for HFIP role in the transformation | 47 |

1. General remarks: C, H and N analyses were carried out locally. NMR data (^1H or ^{13}C) were recorded locally on 400spectrometer in IIT Bombay. HRMS analyses were performed locally. The ionization mechanism used was electrospray in positive and negative ion full scan mode using acetonitrile as solvent and nitrogen gas for desolvation. All, commercially available chemicals were purchased from commercial sources and were used without further purification. All the solvents were dried by standard methods before use.

2. Representative Procedure:

A) General procedure:

A clean and dry Schlenk tube was subjected to vacuum degassing and nitrogen flushing for 5 min. A clean dry stir bar was dropped into the tube and it was set over a magnetic stirrer with nitrogen atmosphere was maintained inside the tube. (under nitrogen atmosphere)

The components were added as follows: Pd(OAc)₂ (1.0 mol%, 2.2 mg), Ag₂O (1.0 mmol., 231 mg), NaOAc (0.5 mmol., 41 mg), iodoarenes (1.0 mmol.) with (then) hexafluoro-2- propanol was added (2.0 mL), followed by benzothiazole (1.0 mmol.). After a final nitrogen flushing of 5 min, the tube was sealed using teflon tape. The reaction mixture was allowed to stir at room temperature (30 °C) for 12 hr. After this the reaction mixture was filtered through a short silica gel filter and washing it with ethyl acetate with the filtrate transferred and subsequently concentrated on a rotary evaporator under vacuum. Purification of the crude was performed using column chromatography with silica gel of 60 Å mesh size.

B) Sequential HFIP-promoted iodination/Pd-catalyzed C—H functionalization strategy.

1) Iodination of arene to aryl iodide (9a-b):

In a clean and oven dried round bottom flask, arene (1.0 mmol.) is treated with I₂ (0.6 mmol., 151 mg), PhI(OAc)₂ (1.1 mmol., 354 mg) and the mixture is grinded using a mortar and pestle at room temperature for 0.5 hr. The semi-solid product slowly solidified, and the formed product was confirmed by GC- MS (EI). The obtained product was next transferred to another clean flask by using 1.0 mL hexafluoro-2- propanol and was directly used for the next catalytic step without purification¹.

3) Product 9(a-b) was prepared according to the general procedure.

C) Synthesis of PMX 610 analog (antitumor agent) (12).

1) Alkylation with methyl iodide:

In a clean and oven dried round bottom flask, catechol (1.0 mmol., 110 mg), MeI (3.0 mmol., 425 mg) and K₂CO₃ (4.0 mmol., 552 mg) were mixed in acetone (6.0 mL) and stirred at room temperature for 12 hr. Product formed was purified by column chromatography and isolated in 95% yield².

2) Iodination:

Product isolated from step (1) is treated with I₂ (0.6 mmol., 151 mg), PhI(OAc)₂ (1.1 mmol., 354 mg) and the mixture is grinded using a mortar and pestle at room temperature for 0.5 hr. The semi-solid product slowly solidified and was product confirmed by GC- MS (EI). Formed product was next transferred by using 1.0 mL hexafluoro-2- propanol and was directly used for the next catalytic step without purification¹.


3) Product (PMX 610 Analog) was prepared according to the general procedure (231 mg, 80% yield) and was obtained as a semi-solid.

D) Synthesis of CJM 126 analog (15).

1) In a clean and oven dried Schlenk tube, N- phenylacetamide (1.0 mmol., 135 mg) and N-iodosuccinimide (1.0 mmol., 224 mg) are mixed and hexafluoro-2- propanol (2.0 mL) was added to this mixture. The reaction mixture was stirred at room temperature for 2 hr. The product was purified and isolated by column chromatography (253 mg, 97% yield)³.

2) Product (15) was prepared according to the general procedure (171 mg, 64% yield) and obtained as a brown solid.

3. Characterization data for substituted benzothiazoles:




2-phenylbenzo[d]thiazole (3a)

Product **3a** was prepared according to the general procedure (194 mg, 92% yield) and obtained as a solid.

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.15 – 8.06 (m, 3H), 7.94 – 7.87 (m, 1H), 7.55 – 7.46 (m, 4H), 7.39 (ddd, $J = 1.2, 7.2, 8.2$ Hz, 1H).

$^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 168.1, 154.2, 135.1, 133.7, 131.0, 129.1, 127.6, 126.4, 125.3, 123.3, 121.7

HRMS: ESI, $(\text{M}+\text{H})^+$ $m/z = 212.0538$ calcd. for $(\text{C}_{13}\text{H}_9\text{NS}+\text{H})^+$, found: 212.0537.




2-(o-tolyl)benzo[d]thiazole (3b)

Product **3b** was prepared according to the general procedure (180 mg, 80% yield) and obtained as a solid.

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.12 (dd, $J = 1.1, 8.2$ Hz, 1H), 7.94 (dd, $J = 1.1, 7.9$ Hz, 1H), 7.77 (dd, $J = 1.4, 7.6$ Hz, 1H), 7.52 (ddd, $J = 1.3, 7.4, 8.8$ Hz, 1H), 7.45 – 7.38 (m, 2H), 7.33 (ddd, $J = 1.9, 7.9, 14.4$ Hz, 2H), 2.67 (s, 3H).

$^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 168.1, 153.9, 137.3, 135.7, 133.2, 131.6, 130.6, 130.1, 126.2, 126.2, 125.2, 123.5, 121.4, 21.4.

HRMS: ESI, $(\text{M}+\text{H})^+$ $m/z = 226.0698$ calcd. for $(\text{C}_{14}\text{H}_{11}\text{NS}+\text{H})^+$, found: 226.0697.




2-(3,5-dimethylphenyl)benzo[d]thiazole (3c)

Product **3c** was prepared according to the general procedure (193 mg, 81% yield) and obtained as a solid.

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.11 – 8.05 (m, 1H), 7.90 (dd, $J = 1.3, 8.0$ Hz, 1H), 7.72 (d, $J = 1.7$ Hz, 2H), 7.49 (ddd, $J = 1.3, 7.2, 8.3$ Hz, 1H), 7.38 (ddd, $J = 1.2, 7.2, 8.2$ Hz, 1H), 7.16 – 7.11 (m, 1H), 2.42 (s, 6H).

$^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 154.2, 138.8, 133.5, 132.8, 126.3, 125.4, 125.1, 123.2, 121.7, 29.8, 21.3.

HRMS: ESI, $(\text{M}+\text{H})^+$ $m/z = 240.0855$ calcd. for $(\text{C}_{15}\text{H}_{13}\text{NS}+\text{H})^+$, found: 240.0855.




2-(3,4-dimethoxyphenyl)benzo[d]thiazole (3d)

Product **3d** was prepared according to the general procedure (227 mg, 84% yield) and obtained as a solid.

^1H NMR (400 MHz, CDCl_3) δ 8.03 (dt, $J = 0.8, 8.2$ Hz, 1H), 7.87 (dd, $J = 1.2, 8.0$ Hz, 1H), 7.71 (d, $J = 2.1$ Hz, 1H), 7.59 (dd, $J = 2.1, 8.4$ Hz, 1H), 7.47 (ddd, $J = 1.3, 7.2, 8.2$ Hz, 1H), 7.35 (td, $J = 1.2, 7.6$ Hz, 1H), 6.94 (d, $J = 8.4$ Hz, 1H), 4.02 (s, 3H), 3.95 (s, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 168.0, 154.2, 151.7, 149.4, 135.0, 126.8, 126.3, 125.0, 122.9, 121.6, 121.2, 111.1, 109.9, 56.2, 56.1.

HRMS: ESI, $(\text{M}+\text{H})^+$ $m/z = 272.0750$ calcd. for $(\text{C}_{15}\text{H}_{13}\text{NO}_2\text{S}+\text{H})^+$, found: 272.0749.




2-(2-methoxyphenyl)benzo[d]thiazole (**3e**)

Product **3e** was prepared according to the general procedure (197 mg, 87% yield) and obtained as a solid.

^1H NMR (400 MHz, CDCl_3) δ 8.54 (dd, $J = 1.8, 7.9$ Hz, 1H), 8.10 (dt, $J = 0.9, 8.2$ Hz, 1H), 7.93 (dt, $J = 0.9, 8.0$ Hz, 1H), 7.48 (dddd, $J = 1.5, 7.2, 8.9, 12.8$ Hz, 2H), 7.37 (ddd, $J = 1.1, 7.2, 8.2$ Hz, 1H), 7.18 – 7.10 (m, 1H), 7.07 (dd, $J = 1.1, 8.4$ Hz, 1H), 4.06 (s, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 163.2, 157.3, 152.3, 136.2, 131.8, 129.6, 126.0, 124.7, 122.9, 122.4, 121.3, 121.3, 111.8, 55.8.

HRMS: ESI, $(\text{M}+\text{Na})^+$ $m/z = 264.0453$ calcd. for $(\text{C}_{14}\text{H}_{11}\text{NOS}+\text{Na})^+$, found: 264.0453.




2-(3,4,5-trimethoxyphenyl)benzo[d]thiazole (**3f**)

Product **3f** was prepared according to the general procedure (252 mg, 84% yield) and obtained as a solid.

^1H NMR (400 MHz, CDCl_3) δ 8.05 (dt, $J = 0.9, 8.1$ Hz, 1H), 7.92 – 7.85 (m, 1H), 7.49 (ddd, $J = 1.3, 7.2, 8.3$ Hz, 1H), 7.38 (ddd, $J = 1.2, 7.2, 8.2$ Hz, 1H), 7.33 (s, 2H), 3.98 (s, 6H), 3.92 (s, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 167.9, 154.2, 153.7, 140.8, 135.1, 129.2, 126.4, 125.2, 123.2, 121.6, 104.9, 61.1, 56.5.

HRMS: ESI, $(\text{M}+\text{Na})^+$ $m/z = 324.0666$ calcd. for $(\text{C}_{16}\text{H}_{15}\text{NO}_3\text{S}+\text{Na})^+$, found: 324.0665.



2-(4-fluorophenyl)benzo[d]thiazole (**3g**)


Product **3g** was prepared according to the general procedure (196 mg, 86% yield) and obtained as a solid.

^1H NMR (400 MHz, CDCl_3) δ 8.13 – 8.03 (m, 3H), 7.89 (d, $J = 7.9$ Hz, 1H), 7.49 (ddd, $J = 1.3, 7.1, 8.3$ Hz, 1H), 7.43 – 7.34 (m, 1H), 7.18 (t, $J = 8.6$ Hz, 2H).

^{13}C NMR (101 MHz, CDCl_3) δ 166.8, 164.5 (d, $J_{\text{CF}} = 252.5$ Hz), 154.2, 135.1, 130.1 (d, $J_{\text{CF}} = 3.0$ Hz), 129.6 (d, $J_{\text{CF}} = 9.0$ Hz), 126.5, 125.3, 123.3, 121.7, 116.2 (d, $J_{\text{CF}} = 22.2$ Hz).

^{19}F NMR (376 MHz, CDCl_3) δ -108.9.

HRMS: ESI, (M+H)⁺ m/z= 230.0434 calcd. for (C₁₃H₈FNS+H)⁺, found: 230.0433.



2-(2-fluorophenyl)benzo[d]thiazole (3h)


Product **3h** was prepared according to the general procedure (185 mg, 81% yield) and obtained as a solid.

¹H NMR (400 MHz, CDCl₃) δ 8.42 (td, *J* = 1.8, 7.7 Hz, 1H), 8.13 (dt, *J* = 0.9, 8.2 Hz, 1H), 7.94 (dt, *J* = 0.9, 8.0 Hz, 1H), 7.56 – 7.37 (m, 3H), 7.37 – 7.28 (m, 1H), 7.24 (ddd, *J* = 1.2, 8.3, 11.2 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃) δ 161.2(d, *J*_{CF} = 6.06Hz), 160.6(d, *J*_{CF} = 254.5Hz), 152.6, 135.8, 161.2(d, *J*_{CF} = 8.0Hz), 132.2(d, *J*_{CF} = 9.09Hz), 129.8(d, *J*_{CF} = 3.0Hz), 126.4, 125.4, 124.8 (d, *J*_{CF} = 4.0Hz), 123.4, 121.5(d, *J*_{CF} = 11.1Hz), 116.5(d, *J*_{CF} = 22.2Hz).

¹⁹F NMR (376 MHz, CDCl₃) δ -111.9.

HRMS: ESI, (M+H)⁺ m/z= 230.0436 calcd. for (C₁₃H₈FNS+H)⁺, found: 230.0435.



2-(4-(trifluoromethyl)phenyl)benzo[d]thiazole (3i)


Product **3i** was prepared according to the general procedure (212 mg, 76% yield) and obtained as a solid.

¹H NMR (400 MHz, CDCl₃) δ 8.23 – 8.17 (m, 2H), 8.11 (dt, *J* = 0.9, 8.2 Hz, 1H), 7.96 – 7.89 (m, 1H), 7.75 (d, *J* = 8.2 Hz, 2H), 7.53 (ddd, *J* = 1.3, 7.2, 8.3 Hz, 1H), 7.43 (td, *J* = 1.2, 7.6 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃) δ 166.0, 154.0, 136.7, 135.2, 132.4(q, *J*_{CF} = 33.3Hz), 127.7, 126.6, 126.0(q, *J*_{CF} = 4.0Hz), 125.8, 123.8(q, *J*_{CF} = 273.7Hz), 123.6, 121.7.

¹⁹F NMR (376 MHz, CDCl₃) δ -62.8.

HRMS: ESI, (M+H)⁺ m/z= 279.0300 calcd. for (C₁₄H₈F₃NS+H)⁺, found: 280.0398.




2-(2-bromophenyl)benzo[d]thiazole (3j)

Product **3j** was prepared according to the general procedure (227 mg, 79% yield) and obtained as a solid.

¹H NMR (400 MHz, CDCl₃) δ 8.15 (dd, *J* = 1.0, 8.2 Hz, 1H), 8.02 – 7.92 (m, 2H), 7.74 (dd, *J* = 1.2, 8.0 Hz, 1H), 7.53 (ddd, *J* = 1.3, 7.2, 8.2 Hz, 1H), 7.44 (tdd, *J* = 1.2, 2.5, 7.1 Hz, 2H), 7.33 (td, *J* = 1.8, 7.7 Hz, 1H)

¹³C NMR (101 MHz, CDCl₃) δ 165.7, 152.8, 136.2, 134.6, 134.2, 132.2, 131.3, 127.7, 126.4, 125.6, 123.7, 122.2, 121.5.

HRMS: ESI, (M+H)⁺ m/z= 291.9615 calcd. for (C₁₃H₈BrNS+H)⁺, found: 291.9615.




2-(4-chlorophenyl)benzo[d]thiazole (3k)

Product **3k** was prepared according to the general procedure (220 mg, 90% yield) and obtained as a solid.

^1H NMR (400 MHz, CDCl_3) δ 8.10 – 8.03 (m, 1H), 8.05 – 7.98 (m, 2H), 7.90 (dd, $J = 1.3, 8.0$ Hz, 1H), 7.54 – 7.45 (m, 2H), 7.45 (d, $J = 1.8$ Hz, 1H), 7.44 – 7.35 (m, 1H).

^{13}C NMR (101 MHz, CDCl_3) δ 166.7, 154.2, 137.1, 135.1, 132.2, 129.4, 128.8, 126.6, 125.5, 123.4, 121.7.

HRMS: ESI, $(\text{M}+\text{H})^+$ $m/z = 246.0146$ calcd. for $(\text{C}_{13}\text{H}_8\text{ClNS}+\text{H})^+$, found: 246.0145.




2-(4-bromophenyl)benzo[d]thiazole (3l)

Product **3l** was prepared according to the general procedure (256 mg, 89% yield) and obtained as a solid.

^1H NMR (400 MHz, CDCl_3) δ 8.07 (d, $J = 8.2$ Hz, 1H), 7.98 – 7.91 (m, 2H), 7.92 – 7.87 (m, 1H), 7.66 – 7.57 (m, 2H), 7.50 (tt, $J = 1.5, 8.4$ Hz, 1H), 7.40 (td, $J = 1.9, 7.5$ Hz, 1H).

^{13}C NMR (101 MHz, CDCl_3) δ 166.8, 154.1, 135.1, 132.6, 132.3, 129.0, 126.6, 125.5, 125.5, 123.4, 121.7.

HRMS: ESI, $(\text{M}+\text{H})^+$ $m/z = 291.9613$ calcd. for $(\text{C}_{13}\text{H}_8\text{BrNS}+\text{H})^+$, found: 291.9613.



2-(3-fluoro-4-methylphenyl)benzo[d]thiazole (3m)


Product **3m** was prepared according to the general procedure (206 mg, 85% yield) and obtained as a solid.

^1H NMR (400 MHz, CDCl_3) δ 8.13 – 8.03 (m, 1H), 7.97 – 7.85 (m, 1H), 7.81 – 7.70 (m, 2H), 7.49 (ddd, $J = 1.3, 7.2, 8.3$ Hz, 1H), 7.38 (ddd, $J = 1.2, 7.2, 8.2$ Hz, 1H), 7.34 – 7.24 (m, 1H), 2.34 (d, $J = 2.0$ Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 166.8(d, $J_{\text{CF}}=3.0\text{Hz}$), 161.6(d, $J_{\text{CF}}=246.4\text{Hz}$), 154.1, 135.1, 133.2(d, $J_{\text{CF}}=8.0\text{Hz}$), 132.1(d, $J_{\text{CF}}=5.0\text{Hz}$), 128.2(d, $J_{\text{CF}}=18.1\text{Hz}$), 126.5, 125.4, 123.3, 123.1(d, $J_{\text{CF}}=3.0\text{Hz}$), 121.7, 114.0(d, $J_{\text{CF}}=25.2\text{Hz}$), 14.8(d, $J_{\text{CF}}=3.0\text{Hz}$).

^{19}F NMR (376 MHz, CDCl_3) δ -116.3.


HRMS: ESI, $(\text{M}+\text{H})^+$ $m/z = 244.0598$ calcd. for $(\text{C}_{14}\text{H}_{10}\text{FNS}+\text{H})^+$, found: 244.0598.



2-([1,1'-biphenyl]-4-yl)benzo[d]thiazole (5a)

Product **5a** was prepared according to the general procedure (238 mg, 83% yield) and obtained as a solid.

^1H NMR (400 MHz, CDCl_3) δ 8.21 – 8.14 (m, 2H), 8.10 (dt, $J = 0.8, 8.2$ Hz, 1H), 7.95 – 7.88 (m, 1H), 7.77 – 7.69 (m, 2H), 7.72 – 7.62 (m, 2H), 7.50 (dddd, $J = 1.5, 6.7, 7.9, 10.7$ Hz, 3H), 7.40 (ddt, $J = 1.3, 7.3, 8.2$ Hz, 2H)
 ^{13}C NMR (101 MHz, CDCl_3) δ 167.8, 154.3, 143.8, 140.1, 135.2, 132.6, 129.0, 128.1, 128.0, 127.7, 127.2, 126.4, 125.3, 123.3, 121.7, 77.4, 77.1, 76.8.
HRMS: ESI, $(\text{M}+\text{Na})^+$ $m/z = 310.0662$ calcd. for $(\text{C}_{19}\text{H}_{13}\text{NS}+\text{Na})^+$, found: 310.0661.




2-(naphthalen-2-yl)benzo[d]thiazole (**5b**)

Product **5b** was prepared according to the general procedure (221 mg, 85% yield) and obtained as a solid.

^1H NMR (400 MHz, CDCl_3) δ 8.59 – 8.54 (m, 1H), 8.21 (dd, $J = 1.8, 8.5$ Hz, 1H), 8.13 (dt, $J = 0.9, 8.2$ Hz, 1H), 8.01 – 7.90 (m, 3H), 7.90 – 7.83 (m, 1H), 7.60 – 7.52 (m, 1H), 7.56 – 7.47 (m, 1H), 7.40 (ddd, $J = 1.2, 7.2, 8.3$ Hz, 1H).

^{13}C NMR (101 MHz, CDCl_3) δ 168.2, 154.3, 135.2, 134.7, 133.3, 131.1, 128.9, 127.9, 127.7, 127.5, 126.9, 126.5, 125.3, 124.5, 123.3, 121.7.

HRMS: ESI, $(\text{M}+\text{H})^+$ $m/z = 262.0691$ calcd. for $(\text{C}_{17}\text{H}_{11}\text{NS}+\text{H})^+$, found: 262.0691.




2-(naphthalen-1-yl)benzo[d]thiazole (**5c**)

Product **5c** was prepared according to the general procedure (229 mg, 88% yield) and obtained as a solid.

^1H NMR (400 MHz, CDCl_3) δ 9.00 (dd, $J = 3.3, 8.7$ Hz, 1H), 8.25 (dt, $J = 1.7, 8.2$ Hz, 1H), 8.03 – 7.91 (m, 4H), 7.65 (ddt, $J = 1.3, 6.9, 8.4$ Hz, 1H), 7.62 – 7.53 (m, 3H), 7.50 – 7.42 (m, 1H).

^{13}C NMR (101 MHz, CDCl_3) δ 167.7, 154.2, 135.5, 134.1, 131.1, 130.9, 130.7, 129.4, 128.5, 127.7, 126.6, 126.3, 126.0, 125.3, 125.0, 123.6, 121.4.

HRMS: ESI, $(\text{M}+\text{Na})^+$ $m/z = 284.0501$ calcd. for $(\text{C}_{17}\text{H}_{11}\text{NS}+\text{Na})^+$, found: 284.0501.




2-(phenanthren-9-yl)benzo[d]thiazole (**5d**)

Product **5d** was prepared according to the general procedure (245 mg, 79% yield) and obtained as a solid.

^1H NMR (400 MHz, CDCl_3) δ 8.96 – 8.90 (m, 1H), 8.79 (dd, $J = 1.6, 8.0$ Hz, 1H), 8.73 (d, $J = 8.3$ Hz, 1H), 8.25 – 8.18 (m, 2H), 8.03 – 7.94 (m, 2H), 7.74 (ddd, $J = 1.6, 6.8, 8.0$ Hz, 2H), 7.70 (ddd, $J = 1.6, 7.0, 8.4$ Hz, 1H), 7.65 (ddd, $J = 1.2, 7.0, 8.1$ Hz, 1H), 7.58 (ddd, $J = 1.3, 7.2, 8.3$ Hz, 1H), 7.48 (ddd, $J = 1.3, 7.2, 8.3$ Hz, 1H).

^{13}C NMR (101 MHz, CDCl_3) δ 167.7, 154.2, 135.5, 131.3, 131.1, 130.9, 130.8, 129.9, 129.5, 129.3, 128.3, 127.5, 127.3, 127.2, 126.8, 126.4, 125.5, 123.7, 123.0, 122.8, 121.5.
HRMS: ESI, $(\text{M}+\text{H})^+$ $m/z=$ 312.0844 calcd. for $(\text{C}_{21}\text{H}_{13}\text{NS}+\text{H})^+$, found: 312.0844.




6-methyl-2-phenylbenzo[d]thiazole (7a)

Product **7a** was prepared according to the general procedure (193 mg, 86% yield) and obtained as a solid.

^1H NMR (400 MHz, CDCl_3) δ 8.13 – 8.03 (m, 2H), 7.96 (d, $J = 8.3$ Hz, 1H), 7.68 (d, $J = 1.7$ Hz, 1H), 7.48 (qd, $J = 1.7, 3.8$ Hz, 3H), 7.30 (dd, $J = 1.7, 8.3$ Hz, 1H), 2.49 (s, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 167.1, 152.3, 135.4, 135.3, 133.8, 130.8, 129.0, 128.0, 127.5, 122.8, 121.4, 21.6.

HRMS: ESI, $(\text{M}+\text{H})^+$ $m/z=$ 226.0694 calcd. for $(\text{C}_{14}\text{H}_{11}\text{NS}+\text{H})^+$, found: 226.0694.




6-methyl-2-(*m*-tolyl)benzo[d]thiazole (7b)

Product **7b** was prepared according to the general procedure (193 mg, 81% yield) and obtained as a solid.

^1H NMR (400 MHz, CDCl_3) δ 7.98 – 7.90 (m, 2H), 7.85 (dt, $J = 1.6, 7.8$ Hz, 1H), 7.68 (d, $J = 1.9$ Hz, 1H), 7.37 (t, $J = 7.6$ Hz, 1H), 7.33 – 7.25 (m, 2H), 2.50 (s, 3H), 2.45 (s, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 167.4, 152.3, 138.9, 135.4, 135.3, 133.7, 131.7, 129.1, 129.0, 128.0, 124.8, 122.7, 121.4, 21.6, 21.4.

HRMS: ESI, $(\text{M}+\text{H})^+$ $m/z=$ 240.0851 calcd. for $(\text{C}_{15}\text{H}_{13}\text{NS}+\text{H})^+$, found: 240.0851.




6-methyl-2-(4-(trifluoromethyl)phenyl)benzo[d]thiazole (7c)

Product **7c** was prepared according to the general procedure (213 mg, 73% yield) and obtained as a solid.

^1H NMR (400 MHz, CDCl_3) δ 8.18 (d, $J = 8.1$ Hz, 2H), 7.98 (d, $J = 8.4$ Hz, 1H), 7.77 – 7.66 (m, 3H), 7.37 – 7.30 (m, 1H), 2.51 (s, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 165.0, 152.2, 136.9, 136.1, 132.4, 132.0, 128.3, 127.6, 125.9 (q, $J_{\text{CF}}=4.0$ Hz), 123.8 (q, $J_{\text{CF}}=273.7$ Hz), 123.1, 121.4, 21.6.

HRMS: ESI, $(\text{M}+\text{H})^+$ $m/z=$ 294.0560 calcd. for $(\text{C}_{15}\text{H}_{10}\text{F}_3\text{NS}+\text{H})^+$, found: 294.0559.




2-(4-bromophenyl)-6-chlorobenzo[d]thiazole (7d)

Product **7d** was prepared according to the general procedure (259 mg, 80% yield) and obtained as a solid.

^1H NMR (400 MHz, CDCl_3) δ 8.03 – 7.92 (m, 3H), 7.86 (d, J = 2.1 Hz, 1H), 7.45 (ddt, J = 2.6, 6.5, 9.0 Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 167.2, 152.7, 137.5, 136.3, 131.8, 131.4, 129.5, 128.8, 127.4, 124.1, 121.4.

HRMS: ESI, $(\text{M}+\text{H})^+$ m/z = 325.9219 calcd. for $(\text{C}_{13}\text{H}_7\text{BrCINS}+\text{H})^+$, found: 325.9219.




6-chloro-2-(4-methoxyphenyl)benzo[d]thiazole (**7e**)

Product **7e** was prepared according to the general procedure (217 mg, 79% yield) and obtained as a solid.

^1H NMR (400 MHz, CDCl_3) δ 8.50 (dd, J = 1.8, 7.9 Hz, 1H), 7.98 (d, J = 8.7 Hz, 1H), 7.88 (d, J = 2.1 Hz, 1H), 7.51 – 7.40 (m, 2H), 7.18 – 7.10 (m, 1H), 7.07 (dd, J = 1.1, 8.4 Hz, 1H), 4.06 (d, J = 1.4 Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 163.7, 157.3, 150.8, 137.5, 132.2, 130.4, 129.5, 126.8, 123.6, 122.0, 121.3, 120.8, 111.8, 55.8

HRMS: ESI, $(\text{M}+\text{H})^+$ m/z = 276.0249 calcd. for $(\text{C}_{14}\text{H}_{10}\text{ClNOS}+\text{H})^+$, found: 276.0249.



2-(4-bromophenyl)-6-fluorobenzo[d]thiazole (**7f**)


Product **7f** was prepared according to the general procedure (217 mg, 79% yield) and obtained as a solid.

^1H NMR (400 MHz, CDCl_3) δ 7.98 (dd, J = 4.8, 9.0 Hz, 1H), 7.92 – 7.84 (m, 2H), 7.64 – 7.56 (m, 2H), 7.60 – 7.51 (m, 1H), 7.22 (td, J = 2.6, 8.9 Hz, 1H).

^{13}C NMR (101 MHz, CDCl_3) δ 166.5(d, J_{CF} =3.0Hz), 160.7(d, J_{CF} =246.4Hz), 150.8(d, J_{CF} =1.0Hz), 136.0(d, J_{CF} =11.1Hz), 132.3, 128.8, 125.6, 124.3(d, J_{CF} =9.0Hz), 115.2(d, J_{CF} =25.2Hz), 107.9(d, J_{CF} =27.2Hz).

^{19}F NMR (376 MHz, CDCl_3) δ -115.21.

HRMS: ESI, $(\text{M}+\text{H})^+$ m/z = 309.9517 calcd. for $(\text{C}_{13}\text{H}_7\text{BrFNS}+\text{H})^+$, found: 309.9516.



6-fluoro-2-(naphthalen-2-yl)benzo[d]thiazole (**7g**)


Product **7g** was prepared according to the general procedure (192 mg, 69% yield) and obtained as a solid.

^1H NMR (400 MHz, CDCl_3) δ 8.93 (dq, J = 0.9, 8.7 Hz, 1H), 8.13 (dd, J = 4.8, 8.9 Hz, 1H), 8.00 (dd, J = 1.2, 8.3 Hz, 1H), 7.92 (ddd, J = 1.5, 7.7, 8.4 Hz, 2H), 7.69 – 7.61 (m, 2H), 7.61 – 7.52 (m, 2H), 7.29 (td, J = 2.6, 8.9 Hz, 1H).

^{13}C NMR (101 MHz, CDCl_3) δ 167.4(d, $J_{\text{CF}}=3.0\text{Hz}$), 160.7(d, $J_{\text{CF}}=246.4\text{Hz}$), 150.9(d, $J_{\text{CF}}=2.0\text{Hz}$), 136.5(d, $J_{\text{CF}}=6.0\text{Hz}$), 134.1, 131.3, 130.6, 130.6, 129.5, 128.6, 127.8, 126.7, 125.9, 125.1, 124.6(d, $J_{\text{CF}}=9.0\text{Hz}$), 115.0(d, $J_{\text{CF}}=25.0\text{Hz}$), 107.7(d, $J_{\text{CF}}=27.0\text{Hz}$).

^{19}F NMR (376 MHz, CDCl_3) δ -115.7.

HRMS: ESI, $(\text{M}+\text{H})^+$ $m/z=280.0592$ calcd. for $(\text{C}_{17}\text{H}_{10}\text{FNS}+\text{H})^+$, found: 280.0591.




2-(4-methoxyphenyl)benzo[d]thiazole (9a)

Product **9a** was prepared according to the general procedure (187 mg, 78% yield) and obtained as a solid.

^1H NMR (400 MHz, CDCl_3) δ 7.99 – 7.85 (m, 3H), 7.82 – 7.74 (m, 1H), 7.38 (ddd, $J = 1.3, 7.2, 8.3$ Hz, 1H), 7.26 (ddd, $J = 1.2, 7.2, 8.2$ Hz, 1H), 6.95 – 6.87 (m, 2H), 3.78 (s, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 168.0, 162.0, 154.3, 134.9, 129.2, 126.5, 126.3, 124.9, 122.9, 121.6, 114.5, 55.5.

HRMS: ESI, $(\text{M}+\text{H})^+$ $m/z=242.0647$ calcd. for $(\text{C}_{14}\text{H}_{11}\text{NOS}+\text{H})^+$, found: 242.0646.




2-(2,4-dimethoxyphenyl)benzo[d]thiazole (9b)

Product **9b** was prepared according to the general procedure (203 mg, 75% yield) and obtained as a solid.

^1H NMR (400 MHz, CDCl_3) δ 8.46 (d, $J = 8.8$ Hz, 1H), 8.04 (dt, $J = 1.0, 8.2$ Hz, 1H), 7.90 (ddd, $J = 0.7, 1.3, 8.0$ Hz, 1H), 7.50 – 7.42 (m, 1H), 7.33 (ddd, $J = 1.2, 7.2, 8.1$ Hz, 1H), 6.67 (dd, $J = 2.4, 8.8$ Hz, 1H), 6.59 (d, $J = 2.4$ Hz, 1H), 4.04 (s, 3H), 3.89 (s, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 163.4, 163.0, 158.7, 152.3, 135.7, 130.9, 126.9, 125.9, 124.2, 122.4, 121.2, 115.8, 106.0, 98.6, 55.8.

HRMS: ESI, $(\text{M}+\text{H})^+$ $m/z=272.0741$ calcd. for $(\text{C}_{15}\text{H}_{13}\text{NO}_2\text{S}+\text{H})^+$, found: 272.0741.




2-(3,4-dimethoxyphenyl)-6-fluorobenzo[d]thiazole (PMX 610 Analog)(12)

^1H NMR (400 MHz, CDCl_3) δ 7.96 (dd, $J = 4.8, 8.9$ Hz, 1H), 7.67 (d, $J = 2.0$ Hz, 1H), 7.61 – 7.52 (m, 2H), 7.20 (td, $J = 2.6, 8.9$ Hz, 1H), 6.95 (d, $J = 8.3$ Hz, 1H), 4.02 (s, 3H), 3.96 (s, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 167.6(d, $J_{\text{CF}}=3.0\text{Hz}$), 160.3(d, $J_{\text{CF}}=246.4\text{Hz}$), 150.9, 150.7(d, $J_{\text{CF}}=1.0\text{Hz}$), 149.4, 135.8(d, $J_{\text{CF}}=12.1\text{Hz}$), 126.4, 123.6(d, $J_{\text{CF}}=9.0\text{Hz}$), 121.0, 114.7(d, $J_{\text{CF}}=25.2\text{Hz}$), 111.0, 109.6, 107.7(d, $J_{\text{CF}}=27.2\text{Hz}$), 56.1, 56.0.

HRMS: ESI, $(\text{M}+\text{H})^+$ $m/z=290.0650$ calcd. for $(\text{C}_{15}\text{H}_{12}\text{FNO}_2\text{S}+\text{H})^+$, found: 290.0650.



N-(4-(benzo[d]thiazol-2-yl)phenyl)acetamide (15)

^1H NMR (400 MHz, DMSO) δ 10.29 (s, 1H), 8.12 – 7.99 (m, 2H), 8.04 – 7.97 (m, 2H), 7.80 – 7.72 (m, 2H), 7.52 (ddd, J = 1.3, 7.2, 8.3 Hz, 1H), 7.42 (ddd, J = 1.2, 7.2, 8.3 Hz, 1H), 2.09 (s, 3H).

^{13}C NMR (101 MHz, DMSO) δ 169.1, 167.2, 153.7, 142.2, 134.4, 128.1, 127.6, 126.7, 125.4, 122.7, 122.4, 119.4, 119.3, 24.2.


HRMS: ESI, (M+H)⁺ m/z = 268.0700 calcd. for (C₁₅H₁₂NO₂S+H)⁺, found: 269.0737.

REFERENCES

- 1) Karade, N. N.; Tiwari, G. B.; Huple, D. B.; Siddiqui, T. A. J. *J. Chem. Res.* 2006, 366-368.
- 2) Kim, Heon; Kim, Yoosik; Kharbash, Raisa; Kwon, Se Hyun; Chang, Yeongrae; Jang. Photopolymer composition, hologram recording medium, optical element, and holog. recording method. WO 2020122678 A1, 2020.
- 3) Ren-Jin Tang.; Thierry Milcent.; Benoit. "Crousse, Regioselective Halogenation of Arenes and Heterocycles in Hexafluoroisopropanol. *J. Org. Chem.* 2018, 83, 2, 930–938.


Schemes with footnotes

Scheme 2: Substrate scope for room temperature C–H functionalization of benzothiazoles.^a




^aPd(OAc)₂ (1.0 mol%), Ag₂O (1.0 mmol), Base (0.5 mmol), iodoarenes (1.0 mmol) in hexafluoro-2-propanol (2.0 mL), followed by benzothiazole (1.0 mmol) and reaction stirred at 30 °C (rt) for 12 hr.

Scheme 3: Room temperature C–H functionalization of benzothiazoles using polyaromatics.^a




^a Pd(OAc)₂ (1.0 mol%), Ag₂O (1.0 mmol), Base (0.5 mmol), iodoarenes (1.0 mmol) in hexafluoro-2-propanol (2.0 mL), followed by benzothiazole (1.0 mmol) and reaction stirred at 30 °C (rt) for 12 hr.

Scheme 4: Substrate scope for room temperature C—H functionalization of substituted benzothiazoles.^a



^a Pd(OAc)₂ (1.0 mol%), Ag₂O (1.0 mmol), Base (0.5 mmol), iodoarenes (1.0 mmol) in hexafluoro-2-propanol (2.0 mL), followed by substituted benzothiazole (1.0 mmol) and reaction stirred at 30 °C (rt) for 12 hr.

Scheme 5: Sequential HFIP-promoted iodination/Pd-catalyzed C—H functionalization strategy.^{a,b}




^a arene (1.0 mmol), PhI(OAc)₂ (1.1 mmol), I₂ (0.6 mmol), grinding at 30°C (rt) for 30 mins, without purification solid transferred to the next process; ^b Pd(OAc)₂ (1.0 mol%), Ag₂O (1.0 mmol), Base (0.5 mmol), iodoarenes (1.0 mmol) in hexafluoro-2-propanol (2.0 mL), followed by benzothiazole (1.0 mmol) and reaction stirred at 30 °C (rt) for 12 hr.

Scheme 6: Synthesis of PMX 610 analog (antitumor agent).^{a,b,c}




^a catechol (1.0 mmol), MeI (3.0 mmol), K₂CO₃ (4.0 mmol), acetone (6.0 mL) stirrer at 30 °C (rt) for 12 hr. product isolated by column chromatography; ^b arene (1.0 mmol), PhI(OAc)₂ (1.1 mmol), I₂ (0.6 mmol), grinding at 30 °C (rt) for 30 mins, without purification solid transferred to the next process; ^a Pd(OAc)₂ (1.0 mol%), Ag₂O (1.0 mmol), Base (0.5 mmol), iodoarenes (1.0 mmol) in hexafluoro-2-propanol (2.0 mL), followed by benzothiazole (1.0 mmol) and reaction stirred at 30 °C (rt) for 12 hr (isolated yields).



Scheme 7: Synthesis of CJM126 precursor (NSC 3444).^{a,b}




^b acetaldehyde (1.0 mmol), NIS (1.0 mmol), HFIP (2.0 mL) added and reaction stirred at 30 °C (rt) for 2 hr, product isolated by column chromatography; ^a Pd(OAc)₂ (1.0 mol%), Ag₂O (0.97 mmol), Base (0.5 mmol), 4-iodoacetanilide (0.97 mmol) in hexafluoro-2-propanol (2.0 mL), followed by benzothiazole (0.97 mmol) and reaction stirred at 30 °C (rt) for 12 hr (isolated yields).

4. ^1H NMR, ^{13}C NMR and ^{19}F NMR Spectra







SJG-SK-529-1H.10.fid
SJG-SK-529-1H




SJG-SK-529-13C.12.fid
SJG-SK-529-13C




ARK-SK-507-1H.1.fid
ARK-SK-507-1H




ARK-SK-507-13C.3.fid
ARK-SK-507-1H







SJG-SK-528-1H.10.fid
SJG-SK-528-1H



SJG-SK-528-13C.12.fid
SJG-SK-528-13C




ARK-SK-509-1H.1.fid
ARK-SK-509-1H



3g


8.11
8.10
8.09
8.09
8.08
8.07
8.06
8.05
8.05
8.05
7.90
7.88
7.52
7.51
7.50
7.49
7.49
7.48
7.47
7.41
7.40
7.38
7.37
7.36
7.21
7.20
7.19
7.18
7.16
7.16
7.15

D (m)
7.39
B (d)
7.89
A (m)
8.07
E (t)
7.18
C (ddd)
7.49




ARK-SK-509-13C.3.fid
ARK-SK-509-13C

166.87
165.84
163.34
154.23
135.19
130.11
130.08
129.70
129.61
126.55
125.38
123.33
121.74
116.40
116.18
77.48
77.16
76.84




--108.91




SJG-SK-523-13C.12.fid
SJG-SK-523-13C

161.94
161.24
161.18
159.42
152.68
135.91
135.83
132.30
132.21
129.90
129.87
126.43
125.42
124.83
124.80
123.41
121.63
121.59
121.52
116.62
116.40
77.48
77.16
76.84





SJG-SK-523-1F.10.fid
SJG-SK-523-1F


--111.91




ARK-SK-513-1H.10.fid
ARK-SK-513-1H




ARK-SK-513-13C.12.fid
ARK-SK-513-13C






SJG-SK-517-13C.12.fid
SJG-SK-517-13C

165.76
152.86
136.26
134.61
134.21
132.29
131.38
127.70
126.42
125.62
123.70
122.21
121.56
77.48
77.16
76.84




ARK-SK-515-1H.10.fid
ARK-SK-515-1H




8.08
8.08
8.06
8.06
8.05
8.03
8.02
8.01
8.00
7.91
7.91
7.89
7.89
7.52
7.52
7.50
7.50
7.48
7.48
7.47
7.47
7.46
7.45
7.42
7.41
7.40
7.38
7.37



3k





ARK-SK-515-1H.11.fid
ARK-SK-515-13C




3I


ARK-SK-512-13C.12.fid
ARK-SK-512-13C





ARK-SK-504-13C.3.fid
ARK-SK-504-13C




SJG-SK-504-19F.10.fid
SJG-SK-504-19F












ARK-SK-510-1H.1.fid
ARK-SK-510-1H




ARK-SK-510-13C.3.fid
ARK-SK-510-13C




ARK-SK-508-1H.1.fid
ARK-SK-508-1H




7a



ARK-SK-508-13C.3.fid
ARK-SK-508-13C




SJG-SK-519-1H.10.fid
SJG-SK-519-1H




7.96
7.94
7.93
7.92
7.86
7.86
7.85
7.84
7.84
7.83
7.69
7.68
7.68
7.39
7.37
7.35
7.31
7.31
7.30
7.29
7.28
7.28
7.27


2.50
2.45





SJG-SK-519-13C.12.fid
SJG-SK-519-13C




SJG-SK-521-1H.10.fid
SJG-SK-521-1H




7c




SJG-SK-521-13C.12.fid
SJG-SK-521-1H




ARK-SK-503-1H.1.fid
ARK-SK-503-1H




7d




ARK-SK-503-13C.3.fid
ARK-SK-503-13C




SJG-SK-532-1H.10.fid
SJG-SK-532-1H






7e




SJG-SK-532-13C.12.fid
SJG-SK-532-13C




SJG-SK-530-1H.10.fid
SJG-SK-530-1H




SJG-SK-530-13C.12.fid
SJG-SK-530-13C







SJG-SK-531-13C.12.fid
SJG-SK-531-13C




SJG-SK-531-1F.10.fid
SJG-SK-531-1F




ARK-SK-502-1H.1.fid
ARK-SK-502-1H





9a





ARK-SK-502-13C.3.fid
ARK-SK-502-13C







SJG-SK-526-1H.10.fid
SJG-SK-526-1H




SJG-SK-526-13C.12.fid
SJG-SK-526-13C




SJG-ARK-SK-516-1H.1.fid
SJG-ARK-SK-516-1H




SJG-ARK-SK-516-13C.3.fid
SJG-ARK-SK-516-13C



1. ^1H NMR of Benzothiazole, HFIP and binary mixture.




The most significant changes found in ^1H NMR, for the binary mixture compared to the individual species, are the downfield shift (de-shielded) of the O-H proton, from a chemical shift value of δ 3.52 ppm to 6.27 ppm ($\Delta\delta = 2.75$).




These data support a H-bonding between the nitrogen atom of the benzothiazole and the exceptionally good hydrogen bond donor HFIP.

2. ^1H NMR of HFIP, mixture of: a) Iodobenzene+Benzothiazole+NaOAc+HFIP, b) Iodobenzene+Benzothiazole+NaOAc c) only HFIP



The most significant changes found in ^1H NMR, for the mixture containing HFIP compared to the one without HFIP, are the downfield shift (deshielded) of the OH, from a frequency of δ 3.52 to 6.84 ppm ($\Delta\delta = 3.32$).



These data follows a similar trend like the binary mixtures and support a H-bonding between the benzothiazole and the sodium acetate with the hydrogen bond donor HFIP.

